The Life Sciences IPOs + Capital Markets team advised Goldman Sachs & Co. LLC and the other underwriters of Taysha Gene Therapies, Inc.’s (Nasdaq: TSHA) initial public offering of 7,869,566 shares of common stock at a price to the public of $20.00 per share and the underwriters purchase of 1,180,434 additional shares of common stock, for total offering gross proceeds of approximately $181 million.
Taysha is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations.
The Goodwin team was led by Robert Puopolo, Marishka DeToy, and Patty Shields, and included Julie Tibbets, Alex Varond, Duncan Greenhalgh, Olivia Uitto, Roger Cohen, Sarah Bock, Janet Andolina, Matt Dunay, and Peter LaVigne.
For more details, read the press release and articles in Endpoints, BioSpace and BioPharma Dive.